Novo Nordisk
NVO
NZ$126.81
Share price
-3.53%
Change (1 day)
-44.40%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Market capitalization of Novo Nordisk (NVO)
Market cap: NZ$566.56 Billion
As of June 2025 Novo Nordisk has a market cap of NZ$566.56 Billion. This makes Novo Nordisk the world's 26th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Novo Nordisk from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | NZ$566.56 B | -16.8% |
| 2024 | NZ$680.98 B | -6.63% |
| 2023 | NZ$729.30 B | 52.06% |
| 2022 | NZ$479.60 B | 28.43% |
| 2021 | NZ$373.43 B | 65.23% |
| 2020 | NZ$226.00 B | 9.41% |
| 2019 | NZ$206.57 B | 23.93% |
| 2018 | NZ$166.68 B | -9.72% |
| 2017 | NZ$184.63 B | 35.81% |
| 2016 | NZ$135.95 B | -38.9% |
| 2015 | NZ$222.52 B | 54.81% |
| 2014 | NZ$143.74 B | 16.73% |
| 2013 | NZ$123.13 B | 11.36% |
| 2012 | NZ$110.57 B | 29.38% |
| 2011 | NZ$85.47 B | -2.37% |
| 2010 | NZ$87.54 B | 57.08% |
| 2009 | NZ$55.73 B | -0.73% |
| 2008 | NZ$56.14 B | 2.48% |
| 2007 | NZ$54.78 B | 45.47% |
| 2006 | NZ$37.65 B | 41.29% |
| 2005 | NZ$26.65 B | 5.55% |
| 2004 | NZ$25.25 B | 16.07% |
| 2003 | NZ$21.75 B | 13.17% |
| 2002 | NZ$19.22 B | -42.57% |
| 2001 | NZ$33.47 B | 20.02% |
| 2000 | NZ$27.89 B | 59.02% |
| 1999 | NZ$17.54 B | -4.11% |
| 1998 | NZ$18.29 B | -1.91% |
| 1997 | NZ$18.65 B | 87.9% |
| 1996 | NZ$9.92 B |
End of Day market cap according to different sources
On Jun 15th, 2025 the market cap of Novo Nordisk was reported to be:
NZ$586.95 Billion
NZ$587.30 Billion
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | NZ$227.90 B | -59.77% | 🇺🇸 USA |
 Eli Lilly LLY | NZ$1.197 T | 111.37% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$162.31 B | -71.35% | 🇺🇸 USA |
 Sanofi SNY | NZ$201.30 B | -64.47% | 🇫🇷 France |